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Classical HLA-DRB1 and DPB1 alleles account for HLA
associations with primary biliary cirrhosis
P Invernizzi1,2, M Ransom3, S Raychaudhuri4,5,6, R Kosoy3, A Lleo2, R Shigeta3, A Franke7, F Bossa8, CI Amos9, PK Gregersen10,
KA Siminovitch11,12, D Cusi13,14, PIW de Bakker4,6,15, M Podda2, ME Gershwin1, MF Seldin1,3 and The Italian PBC Genetics Study Group16
Susceptibility to primary biliary cirrhosis (PBC) is strongly associated with human leukocyte antigen (HLA)-region polymorphisms.
To determine if associations can be explained by classical HLA determinants, we studied Italian, 676 cases and 1440 controls,
genotyped with dense single-nucleotide polymorphisms (SNPs) for which classical HLA alleles and amino acids were imputed.
Although previous genome-wide association studies and our results show stronger SNP associations near DQB1, we demonstrate
that the HLA signals can be attributed to classical DRB1 and DPB1 genes. Strong support for the predominant role of DRB1
is provided by our conditional analyses. We also demonstrate an independent association of DPB1. Specific HLA-DRB1 genes
(*08, *11 and *14) account for most of the DRB1 association signal. Consistent with previous studies, DRB1*08 (P¼ 1.59" 10# 11) was
the strongest predisposing allele, whereas DRB1*11 (P¼ 1.42" 10# 10) was protective. Additionally, DRB1*14 and the DPB1
association (DPB1*03:01; P¼ 9.18" 10# 7) were predisposing risk alleles. No signal was observed in the HLA class 1 or class 3
regions. These findings better define the association of PBC with HLA and specifically support the role of classical HLA-DRB1 and
DPB1 genes and alleles in susceptibility to PBC.
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INTRODUCTION
The human major histocompatibility complex, human leukocyte
antigen (HLA), has been implicated in the etiopathogenesis of
primary biliary cirrhosis (PBC), similar to many other autoimmune
diseases. Genome-wide association studies (GWAS) of PBC,
including our own, find the strongest association with single-
nucleotide polymorphisms (SNPs) within the HLA region.1–3 In
these studies, the peak association signal is between HLA-DQA1
and HLA-DQB1. Multiple studies of PBC also show association with
particular classical HLA alleles in PBC (reviewed in Invernizzi4).
These studies have variably implicated different DRB1 alleles in the
European populations with most studies, including all larger
cohorts showing association of DRB1*08.5,6 Our previous studies in
an Italian cohort with PBC showed the association of DRB1*08 as
predisposing, and DRB1*11 and DRB1*13 as protective alleles.6 A
study using a small cohort (32 German PBC cases and 47 controls)
suggest that DPB1 associations may also be present in Europeans.7
However, a comprehensive study of the HLA region associations
has not been performed, and like other autoimmune diseases, it is
unclear which determinants are actually causally related to
pathogenesis.
To further study the HLA associations in PBC, in the current
study, we used the most recent advances in imputation
algorithms and sequence information resources, including the
1000 genome database to accurately impute missing SNPs, and
importantly, HLA classical alleles. Specifically, our investigation
rests on recent development and resources for imputing HLA
classical alleles, including a reference set of European subjects.8
For our study, we used an inference set of SNP genotypes from
both GWAS and a designed chip array, the Immunochip,9 which
contains a set of SNPs that have been used in multiple studies of
HLA.10 We perform a series of conditioning analyses that clarify
which HLA genes and alleles underlie the major component of the
genetic associations of PBC.
RESULTS
Analyses show strong association of imputed SNPs and HLA
determinants
To further define PBC–HLA region associations, we analyzed
association using imputed genotypes with high probabilities and
information scores (see Materials and methods). These studies
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utilized genotypes from both GWAS and Immunochip arrays that
contained large numbers of SNPs in the major histocompatibility
complex region (Table 1, Supplementary Table S1, and see
Materials and methods). Strong association was observed with
the peak association (P¼ 9.83" 10# 17), with rs115721871 at
position 32653792, distal to DQB1 (Figure 1a, Table 2 and
Supplementary Table S2). Although the strongest associations
were with non-coding SNPs, multiple classical genes in HLA show
strong association with PBC (Table 2). For the classical HLA genes,
the strongest association was with DRB*08 (P¼ 1.59" 10# 11). The
DQB1*04:02 and DQA1*04:01 in tight linkage disequilibrium (LD)
with DRB*08 (r2¼ 0.84 and 0.89, respectively) showed nearly
equivalent signals (1.38" 10# 10, 1.90" 10# 10, respectively). Very
strong association was also observed for DRB1*11 (P¼ 1.42" 10
#10) with a weaker association with the DQB1 allele (DQB1*03:01,
P¼ 6.10" 10# 9) that is in LD (r2¼ 0.75) with DRB1*11. Less strong
associations were observed with DRB1*14, DQB1*05:03
(6.89" 10# 7 and 6.21" 10# 7, respectively) and DPB1*03:01
(P¼ 9.18" 10# 7). DQB1*05:03 is in nearly complete LD with
DRB1*14 (r2¼ 0.97). DPB1*03:01 is not in LD with any of the DRB1,
DQB1 or DQA1 classical alleles or amino acids (AAs; r2o0.01).
There was no association (P410# 4) observed for classical alleles
in HLA A, B, C or DPA1.
As expected from the analysis of classical HLA alleles, PBC also
showed strong association with specific AAs in these genes. Most
of the HLA AA showing association signals corresponded to the
key residues that distinguish the specific classical alleles, which for
DRB1, included lysine (L) at AA74 in DRB1 (DRB*08), glutamate (E)
at AA58 (DRB*11), alanine (A) at AA57 (DRB1*14) and histidine (H)
at AA60 (DRB1*14). Similar results were observed for specific DQB1
and DQA1 AAs that are in strong LD with specific DRB1 alleles and
AAs (Supplementary Table S2).
Conditioning studies using classical HLA genes
To examine whether these associations could be explained for by
known coding differences in genes, we next performed a series of
conditional analyses. These studies were done by conditioning on
a combination of the alleles from an HLA gene (for example, DRB1)
to control for the association that might be attributable to each
gene, albeit some of the effect may not be directly attributed to
that gene because of extensive LD across this region. The residual
signals after controlling for the effect of various combinations of
classical alleles and AA residues in these HLA genes show that
both DRB1 and DQB1 could account for most of the association
signal (Figure 1b–e, Table 2 and Supplementary Table S3). In
addition, the signal in the DPB1 region was only marginally
decreased, conditioning on DRB1, DQB1 or DQA1. Conditioning on
DPB1 eliminated the signal in the DPB1 region and showed a
modest increase in the signal in the across DRB1, DQA1 and DQB1.
To further assess these conditional analyses, we also examined
the relative difference of the conditioning by different HLA genes
by examining beta estimates and their differences. The beta
estimate is the measure of the increase in log-odds that can be
attributed to each copy of a given minor allele. The largest effect is
from the composite of DRB1 alleles as shown by the residual beta
estimates (and odds ratios (ORs)) after conditioning and the mean
change in the beta estimates (Table 3). This is most evident
examining the SNPs with the strongest signals from association
(original signalo5" 10# 8). For example, the DRB1 conditioning
had a much larger mean change in beta estimate (# 0.424)
compared with DQB1 (# 0.236) (P-value o10# 10, paired t-test).
Additional conditional analyses using combinations with DQA1
demonstrated that DQA1 could not substitute for DRB1 or DPB1 in
any of the combinations tested (data not shown).
Conditioning on specific HLA alleles
We next examined the effect of conditioning on specific DRB1,
DQA1, DQB1 and DPB1 classical genes and AAs. A clear pattern
emerged showing that the association of groups of SNPs was
specifically controlled by different alleles. These results are
highlighted in Table 4, and in a more complete version
Supplementary Table S3. Individually, the specific SNPs condi-
tioned a part of the association signal largely corresponding to
those SNPs in moderate or strong LD (r240.5) with the particular
classical specificity or AA. Similar effects were observed for specific
alleles in one gene in strong LD with another gene. This is
particularly evident for the DRB1*14 and DQB1*05:03, in which the
effects of controlling for either of these alleles was virtually
indistinguishable (Supplementary Table S3). Other pairs (for
example, DRB1*08 and DQB1*04:02) showed small but consistent
differences in which the DRB1 allele diminished more signal than
when the DQB1 allele was used in the conditioning analyses
(Supplementary Table S3). Notably, the strongest AA association
was at position 74 that is in the antigen-binding pocket of
DRB1.11,12
Similar to when we conditioned on genes (‘all’ alleles at a
particular gene), the DPB1 region SNP signal was only substantially
reduced when DPB1*03:01 (Table 4 and Supplementary Table S3)
or when specific DPB1 AAs were used in conditioning. The
strongest effects were observed for the lysine at AA position 11
and the methionine at AA position 76 that are both members of
the 16 AA in the putative antigen-binding pocket of this gene.11
Thus, the vast majority of the HLA region association signal can
be accounted individually by conditioning on one of four specific
Table 1. Summary of subject genotyping information
GWASb ICc GWAS-only IC-only Bothd Total
Genotypinga
Italian PBC cases 453 622 54 223 399 676
Italian controls 1042 597 843 398 199 1440
GWAS IC GWAS-only IC-only Both Total
MHC region SNP genotypes
Number of SNPse 1548 4885 604 3941 944 5489
SNPs overlaping 1000 genome referencef 1435 4386 595 3546 840 4981
SNPs overlaping HLA referencef 648 1444 166 962 482 1610
Abbreviations: GWAS, genome-wide association study; IC, Immunochip; HLA, human leukocyte antigen; PBC, primary biliary cirrhosis; SNP, single-nucleotide
polymorphism. aAdditional details on subject set genotyping is in Supplementary Table S1. bGWAS: genotyped using Illumina platforms with 4550 K GWAS
SNPs. The samples included in previous GWAS study. cIC: subjects genotyped using IC array. dSubjects genotyped using both GWAS platform and IC array.
eNumber of SNPs within the region (chromosome 6bps 28911802–33813043 (HG19 map)) used for analyses. fNumber of SNPs genotyped in region that
overlap the reference sets used for imputation.
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alleles, three in DRB1 (*08, *11, and *14) and one in DPB1 (*03:01).
Combinations of these specific alleles accounted for most of the
remaining signal (Supplementary Table S3 and Figure 1f) and are
also reflected in the strong reduction in beta estimates (Table 3).
However, there are signals from several SNPs in the DRB1–DQB1
region that are not accounted for by these conditioning studies.
None of these SNPs with signals Po10# 5 after conditioning on
DRB*08, *11 and *14, and DPB1*03:01 were among the stronger
associated SNPs before conditioning (all with original association
P-values410# 6). In particular, the strongest associated SNP after
conditioning (rs9268668, P¼ 1.67" 10# 7) showed no signal
before conditioning (P¼ 0.40). Whether these residual or new
signals are also because of other specific classical HLA genes is not
clear; however, conditioning on ‘all’ DRB1 and DPB1 alleles ablated
all signals with resulting P-values410# 5 (Figure 1f), suggesting
that additional sequence differences (for example, putative
regulatory SNPs) do not have to be postulated.
Most of the signal observed for specific AAs was also specifically
eliminated when conditioning on the DRB1 or DPB1 classical
alleles. However, there were several exceptions in which the
association signal was not readily decreased by controlling for
single classical HLA alleles. These AAs included DRB1-AA47F, DRB1
AA74A, DQB1-AA26G and DQB1-AA74S. For these AAs, the signal
was ablated when conditioning on two DRB1 alleles (DRB1*08 and
DRB1*11) (Supplementary Table S3). Conversely, conditioning on
these AA could not account for the association of the most of the
other SNPs that were not ablated by single classical HLA alleles
(Supplementary Table S3). Therefore, it may be less likely that
these particular AAs are critical to explaining the association
patterns we observed. However, we cannot exclude a specific
functional role for these AAs, and it is notable that DRB1-AA47 and
DRB1-AA74 are both in the antigen-binding pocket of DRB111,12
and that conditioning on DRB1-AA47F did ablate several of the
association signals that were not controlled by individual DRB1
classical alleles.
Genotypic associations
We also examined genotypic associations, including combinations
of susceptibility alleles, and combinations of risk susceptibility and
protective alleles. Examining individuals with combinations of risk
alleles, DRB1*08 combined with DPB1*03:01 or DRB1*14 combined
with DPB1*03:01, we found higher ORs for disease association than
when examining only individuals with single susceptibility alleles
(Supplementary Table S4). There were insufficient numbers of
DRB1*08/DRB1*14 (frequency o1%) to evaluate these hetero-
Figure 1. Analysis of the HLA region association signals in PBC. In each panel, the symbols show the strength of the association signal
(ordinate) for the corresponding position (Mb, HG19) on chromosome 6 (abscissa). For panel (a), the P-value before conditioning is shown.
For panels (b–f ) the P-values are shown after conditioning on the HLA determinant(s) indicated in the panel. The blue color-coded symbols
denote the strongest associated marker with P-valueo10# 6, and the other markers are color-coded to indicate marker LD with the strongest
associated marker: Markers with strong LD (r240.8) (red); moderate LD (r240.5) (orange), weak LD (r240.2) (yellow) and little or no LD
(open symbols) are shown. The SNPs with the strongest associations were rs115721871 at bp 32653792 (panels a and d), rs9277558 at
bp 33056711 (panels b and c) and rs9268668 at bp 32413889 (panel f ).
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zygote genotypes. The increased risk of the combining DPB1*03:01
with DRB1*08 or DRB1*14 was observed whether DPB1*0301 was
on the same or different haplotype as that of the DRB1 risk allele
(Supplementary Table S4). When risk alleles were combined with
the DRB1*11 protective allele the ORs were near 1 and there was
no significant association with disease.
Finally, we also examined the cumulative combination of risk
predisposing and protective alleles (Table 5 and Supplementary
Table S4). The count of predisposing alleles minus protective
alleles showed a strong correspondence with the OR for PBC.
Individuals with an excess of one or two, or more risk alleles
showed an OR of 3.05 and 5.25 between cases and controls, and
conversely, individuals with an excess of one or two, or more
protective alleles had OR of 0.5 or 0.38, respectively (Table 5). All
results were compatible with an additive model of action between
each of the alleles similar to our previous observations.6
DISCUSSION
The current study of PBC association with HLA differs from
previous investigations by providing the most comprehensive
analysis of the entire HLA region while correcting for multiple
confounding factors. Our results are consistent with a
predominant role for class II genes and, we believe, exclude any
substantial effect from either HLA class I or class III genes (there
were no residual signals for these genes with Po0.0005 after
accounting for class II genes). This contrasts other autoimmune
diseases in which HLA class I or class III has a predominant role (for
example, myasthenia gravis13) or strong class I gene effects are
observed independent of class II associations for example, type 1
diabetes14 and multiple sclerosis15,16).
Our study strongly suggests that the major gene in HLA that
underlies susceptibility to PBC is DRB1. Overall, DRB1 alleles show
the strongest associations and conditioning studies show that
DRB1 could account for almost all (except the DPB1 region) of the
association signal. HLA-DQB1 shows association that is only
marginally less than that observed for DRB1. However, several
points suggest that these associations are secondary to the strong
LD between DRB1 and DQB1: (1) the overall strength of association
of particular DRB1 alleles is stronger than the corresponding DQB1
allele; (2) conditioning on DRB1 could account for all DQB1
associations; and (3) residual beta-estimates after conditioning
showed a substantially stronger DRB1 than DQB1 effect.
In addition, our study provides strong evidence for an
independent effect of DPB1. Although previous studies have, as
indicated in the introduction, suggested DPB1 associations in PBC,
Table 2. Summary of association results and conditioning studies of HLA alleles in PBCa
Marker/AA/
HLA
determinantb
Base pair
position
(HG19)c
Allele 1
(minor
allele)d
Allele 2 MAF
(case)e
MAF
(control)
P-valuef OR minor
allele
Cond. P-value
DRB1g
Cond. P-value
DPB1g
Cond. P-value
DRB1 and
DPB1g
rs115721871 32653792 A G 0.17 0.08 9.8E-17 2.61 9.4E-02 1.3E-19 1.2E-01
rs4246055 32592360 C T 0.19 0.10 2.9E-16 2.47 2.1E-02 1.6E-19 2.8E-02
rs114183935 32655730 A G 0.59 0.43 8.1E-16 1.80 1.9E-02 1.2E-18 3.1E-02
rs114432443 32652278 T C 0.39 0.53 4.6E-15 0.55 2.3E-02 1.4E-17 2.8E-02
rs116493712 32669767 T C 0.57 0.46 1.1E-09 1.56 2.6E-01 5.2E-10 1.8E-01
rs114796881 32664960 A G 0.30 0.41 1.2E-09 0.63 3.9E-01 1.8E-10 3.7E-01
rs114327274 32289594 A G 0.24 0.17 4.1E-08 1.66 1.2E-01 1.9E-08 1.2E-01
rs116348417 32389648 A G 0.26 0.37 4.9E-08 0.66 5.2E-01 6.2E-11 5.7E-01
HLA-
DRB1*08
32552064 SPEC OTHER 0.08 0.03 1.6E-11 3.22 1.0Eþ 00 7.3E-13 1.0Eþ 00
HLA-
DQB1*04:02
32631061 SPEC OTHER 0.07 0.03 1.4E-10 3.16 6.8E-01 9.0E-12 4.5E-01
HLA-
DRB1*11
32552064 SPEC OTHER 0.15 0.26 1.4E-10 0.55 1.0Eþ 00 9.4E-13 8.3E-01
HLA-
DQA1*04:01
32608306 SPEC OTHER 0.07 0.02 1.9E-10 0.32 6.5E-01 9.9E-12 5.0E-01
HLA-
DQB1*03:01
32631061 SPEC OTHER 0.21 0.31 6.1E-09 0.61 8.9E-01 3.8E-10 4.5E-01
HLA-
DQB1*05:03
32631061 SPEC OTHER 0.09 0.05 6.2E-07 2.14 7.6E-01 8.2E-09 1.0Eþ 00
HLA-
DRB1*14
32552064 SPEC OTHER 0.09 0.05 6.9E-07 2.12 1.0Eþ 00 8.8E-09 1.0Eþ 00
HLA-
DPB1*03:01
33049368 DET OTHER 0.16 0.10 9.2E-07 1.78 4.2E-06 1.0Eþ 00 1.0Eþ 00
DRB1-AA74 32551948 OTHER A 0.43 0.31 1.2E-11 1.70 5.9E-01 3.2E-12 9.9E-01
DRB1-AA74 32551948 L OTHER 0.08 0.03 1.3E-11 3.23 2.9E-01 6.1E-13 2.0E-01
DQA1-AA69 32609279 T OTHER 0.08 0.03 2.7E-11 3.21 6.0E-01 8.5E-13 6.4E-01
DRB1-AA58 32551996 E A 0.15 0.26 1.5E-10 0.55 1.0Eþ 00 9.4E-13 1.0Eþ 00
Abbreviations: AA, amino acids; HLA, human leukocyte antigen; MAF, Minor allele frequencies; OR, odds ratio; PBC, primary biliary cirrhosis. aThis table provides a
summary of results before and after conditioning on particular HLA determinants and includes: 1) the top four imputed SNPs (rows 1–4); 2) top four genotyped
SNPs (rows 5–8); 3) all classical HLA determinants with P-valueso10–6 (rows 9–16); and 4) the top four HLA AA associations (rows 17–20). P-values after
conditioning on particular HLA genes (see methods) are also shown. The P-values were determined using SNPTEST V2 (see Materials and methods) and used the
genotype probabilities. A complete summary of strongly association markers is provided in Supplementary Table S1. bThe SNP name, classical HLA determinant or
AA is shown. cThe position corresponding to the marker is shown (chromosomal base pair positions from HG19). dAllele 1 is the minor allele used for the analysis.
For sequences designated with AA numbers, the symbol refers to the allele symbol corresponds to standard AA nomenclature. Where the AA is compared with
multiple other AAs, ‘Other’ is used to represent all alternative AAs. The AA position includes the leader sequence (for example, DRB1* position 104 is the same as
AA position 74 without the leader sequence). Where HLA determinants are provided, the specificity is compared with not having the specificity (OTHER). eMAF
were estimated from probabilities (SNPTEST V2). fP-values before conditioning using population substructure and gender as covariates. gP-value after conditioning
on the allele(s) listed in the heading line.
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these were based on small subject sets and were difficult to
evaluate. Our study demonstrates that the association of DPB1
cannot be accounted for by controlling for other HLA region
genes. These results are also consistent with findings in some, but
not other, autoimmune diseases in which an independent effect
of DPB1 has been reported. These include juvenile idiopathic
arthritis,17 type 1 diabetes,18 multiple sclerosis16,19 and particular
autoantibodies in systemic lupus erythematosus.20
Table 4. Conditioning on specific HLA DRB1 and DPB1 alleles
Groupa Marker/amino acid/HLA
determinantb
Base pair
position (HG19)c
P-valued Cond. P-value
DRB1*08e
Cond. P-value
DRB1*11e
Cond. P-value
DRB1*14e
Cond. P-value
DPB1*03:01e
1 rs114991247 32583504 5.45E-13 2.41E-03 3.96E-13 2.15E-18 3.75E-14
1 rs116240177 32561662 8.20E-13 4.82E-03 1.17E-12 3.66E-18 4.29E-14
1 DRB1-AA74L 32551948 1.33E-11 4.72E-01 2.26E-11 3.67E-16 1.48E-12
1 HLA-DRB1*08 32552064 1.59E-11 1.00Eþ00 2.73E-11 4.55E-16 1.77E-12
1 DQA1-AA69T 32609279 2.75E-11 8.93E-01 3.55E-11 5.99E-16 2.35E-12
1 HLA-DQB1*04:02 32631061 1.38E-10 5.79E-01 1.86E-10 4.02E-15 1.63E-11
1 HLA-DQA1*04:01 32608306 1.90E-10 9.58E-01 1.73E-10 5.55E-15 2.01E-11
2 rs9461776 32575735 3.02E-12 2.39E-14 3.35E-03 9.62E-15 1.53E-15
2 rs115671039 32603212 1.98E-11 9.29E-13 4.62E-02 5.22E-13 2.91E-14
2 HLA-DRB1*11 32552064 1.42E-10 1.34E-12 9.99E-01 4.34E-13 9.25E-14
2 DRB1-AA58E 32551996 1.45E-10 1.34E-12 9.98E-01 4.38E-13 9.30E-14
2 DQB1-AA71T 32632646 5.25E-10 3.65E-09 2.62E-04 4.68E-10 1.69E-12
2 HLA-DQB1*03:01 32631061 6.10E-09 3.29E-10 9.76E-01 3.95E-10 3.25E-11
3 rs380911 32209451 8.94E-09 1.36E-10 4.52E-06 3.71E-04 5.26E-09
3 rs115240978 32672383 1.28E-08 1.30E-10 2.24E-06 6.75E-03 8.16E-10
3 HLA-DQB1*05:03 32631061 6.21E-07 4.79E-09 5.13E-05 6.15E-01 2.31E-08
3 HLA-DRB1*14 32552064 6.89E-07 5.29E-09 4.83E-05 9.99E-01 2.46E-08
3 DRB1-AA57A 32551999 6.90E-07 5.29E-09 4.82E-05 9.99E-01 2.46E-08
3 DRB1-AA60H 32551990 6.90E-07 5.29E-09 4.82E-05 9.99E-01 2.46E-08
4 rs116751915 33052502 8.11E-09 9.21E-09 3.09E-06 1.76E-10 1.69E-04
4 rs114761768 33050442 1.79E-08 3.09E-08 4.73E-06 4.90E-10 3.98E-04
4 DPB1-AA76M 33048662 6.13E-08 3.78E-07 2.11E-05 1.07E-08 8.71E-03
4 DPB1-AA170I 33052958 1.06E-07 2.61E-07 1.61E-05 3.21E-09 8.41E-03
4 HLA-DPB1*03:01 33049368 9.18E-07 2.05E-06 1.01E-06 3.70E-09 9.98E-01
Abbreviations: AA, amino acid; Cond., conditioning; HLA, human leukocyte antigen; OR, odds ratio; SNP, single-nucleotide polymorphism. aThe group
corresponds to those markers that are successfully controlled by specific HLA alleles (P-value after conditioning is 41" 10-4. The bold highlighted P-values
indicate the P-values used in the ‘group’ assignment. For each group, the following are shown in this abbreviated summary: i) the two SNPs with the strongest
association in the group; ii) the two HLA AA with the strongest association; and iii) all classical HLA alleles with Po10-6 before conditioning. The P-values were
determined using SNPTEST V2 (see methods) and used the genotype probabilities. A more complete summary of strongly association markers is provided in
Supplementary Table S2. bThe SNP name, classical HLA determinant or AA is shown. For the AA, the letter following the residue number provides the relevant
AA. cThe position corresponding to the marker is shown (chromosomal base pair positions from HG19). dP-values after conditioning using population
substructure and gender as covariates. eP-values after Cond on the allele(s) listed in the heading line.
Table 3. Comparison of residual association beta estimates and ORs after conditioning studies
All markersa Associationb Controlled
DRB1c
Controlled
DQB1
Controlled
DQA1
Controlled
DPB1
Controlled
DRB1 and
DPB1
Controlled
DQB1 and
DPB1
Controlled DRB1*8,
11, 14 and
DPB1*03:01
Mean B
estimate
0.242 0.188 0.205 0.211 0.237 0.180 0.197 0.190
Mean change
in beta
estimate
Reference # 0.055 # 0.037 # 0.026 # 0.005 # 0.062 # 0.045 # 0.052
Mean OR 1.274 1.207 1.228 1.234 1.268 1.197 1.218 1.209
SNPso5E-8d Association Controlled
DRB1
Controlled
DQB1
Controlled
DQA1
Controlled
DPB1
Controlled
DRB1 and
DPB1
Controlled
DQB1 and
DPB1
Controlled DRB1*8,
11, 14 and
DPB1*03:01
Mean change
in beta
estimate
Reference # 0.424 # 0.236 # 0.229 # 0.005 # 0.430 # 0.240 # 0.410
Mean OR 2.03 1.18 1.35 1.41 1.79 1.17 1.34 1.20
Abbreviations: AA, amino acid; HLA, human leukocyte antigen; MHC, major histocompatibility complex; OR, odds ratio; PBC, primary biliary cirrhosis; SNP,
single-nucleotide polymorphism. aAll markers including SNPs (MHC region), classical HLA determinants and HLA AAs. bThe beta estimate, change in beta
estimate and odds ratios from SNPTESTV2 score test (see methods). cResults after conditioning on the indicated HLA genes or alleles. dResults using only
markers with P-valueso5" 10# 8 in the initial association tests.
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We note that our study does not directly address whether DRB3,
DRB4, DRB5 or structural variations might have additional
independent associations. At present, such studies are challenging
because of absence of reference sets for imputation and/or
difficulty in assessing these polymorphisms, including whether
missing genotypes (excluded SNPs with call rates o0. 95) may
have excluded analysis or inclusion of SNPs within these genes in
available arrays.
This study has also addressed the association of specific HLA-
gene alleles. Most of the HLA association with PBC can be
attributed to specific associations with DRB1*08, DRB1*11,
DRB1*14 and DPB1*03:01. DRB1*08 has the strongest association,
followed by DRB1*11, consistent with several previous studies.6,7
PBC associations with DRB1*14 has not been previously
demonstrated; however, this weaker effect is supported by our
conditioning studies that show that this classical allele can control
for a set of associated SNPs and AAs that are not strongly
influenced by other classical alleles (Table 3 and Supplementary
Table S3). The DPB1*0301 association is consistent with a previous
study of a small German cohort.7
In a previous study, we observed that DRB1*13 was a protective
allele.6 In the current study, the association of DRB1*13 was weak
(P¼ 4.9" 10# 3, OR¼ 0.69, 95% confidence limits¼ 0.53–0.89)
compared with the previous study (P¼ 3.6" 10# 6). This may be
because of several factors: (1) the previous study did not explicitly
control for population substructure; (2) the overlap of subjects
with the previous study iso25% and the difference may reflect
statistical noise; and (3) the previous study used DNA typing rather
than the imputation used in the current study. It may be worth
noting that DRB1*13 like DRB1*11 has an alanine at AA position 74
and thus contributes to the protective effect observed for this AA
(P¼ 1.33" 10# 11, Supplementary Table S3). Similarly, our pre-
vious study6 showed only a marginal association of DRB1*14
(uncorrected P-value¼ 0.004) compared with a strong association
(P¼ 6.9" 10# 7) observed in our current study. Here, the
conditioning study results, including the effect of controlling
SNPs with very strong associations (see group 3, Table 4), provide
additional support for the role of DRB1*14.
Finally, we have also considered specific HLA AAs. Most of the
associated AAs are both nearly unique to the specific HLA classical
alleles discussed above and also correspond to critical residues for
the antigen-binding pocket. Thus, associated AAs in DRB1 at AA
positions 37, 47, 57, 60, 67, 70 and 74; and DPB1 at AA positions 9,
11, 76, 84, 87 are antigen-pocket AAs.11,12 Consistent with our
results, strong associations have been recently observed with
serine at position 57 and leucine at position 74 in a Japanese PBC
cohort.21 We also note that many of the associated DQB1 AAs are
also in critical residues for antigen binding (DQB1-AA13, 26, 70, 71,
74).11,12 Of the DRB1 associated, only AA58 is not among the AAs
in this functional class, whereas for DQB1, several are not in this
functional class (DQB1-AA45, 56, 75, 167, 185).
In conclusion, the most parsimonious explanation consistent
with the current study is that classical HLA genes and the coding
variations within these genes are responsible for the HLA
associations with PBC. Although we cannot exclude the possibility
that other sequence variations affecting, for example, gene
regulation could be important, our data indicates that a limited
set of classical DRB1 and DPB1 alleles are sufficient to explain the
HLA associations with this disease. We believe the current data
provides cogent information for understanding HLA-associations
in PBC. Studies in other ethnic groups both within Europe and in
other continental groups will also be important in further
definition of the role of particular HLA genes and alleles. Lastly,
our results provide additional rational for functional studies
examining specific HLA genes and their relative binding to the
putative disease-associated epitopes of the PDC-E2, the immuno-
dominant autoantigen epitopes of PBC.22,23
MATERIALS AND METHODS
Study population and design
The Italian PBC cases were obtained through a multi-center study and met
internationally accepted criteria for the diagnosis of PBC as detailed in a
previous study.6 Each of the included cases also met ancestry criteria as
defined below (see Ancestry). Controls were derived from several sources
and this sample set information is detailed in Supplementary Table S1.
After data filtering and ancestry, analyses contained 676 Italian PBC cases
and 1440 Italian controls. All subjects enrolled in the study provided
written informed consent and the study followed ethical guidelines of the
most recent revision of the Declaration of Helsinki (Edinburgh, 2000).
All samples were genotyped with either Illumina (San Diego, CA, USA)
genome-wide and/or Immunochip SNP platforms, and the participants
included the data set from our previous GWAS as well as new samples (see
Supplementary Table S1). With the exception of ancestry information and
assessment of relatedness, the current study was restricted to genotypes in
an approximately 4Mb segment of human chromosome 6 (bps
28911802–33813043, HG19 map). This data set comprised a minimum of
1548 and a maximum of 5489 genotyped SNPs in each individual
(Supplementary Table S1) and was used for the SNP and HLA imputations
(see Imputation).
Data filtering
We used stringent quality-control criteria to ensure that high-quality data
were included in the analyses. We excluded individuals who had 45%
missing data, and all individuals with cryptic relatedness and duplicate
samples based on identity-by-descent status for genome-wide SNPs
(PI^40.15) using PLINK.24
We included only SNPs with o5% missing data, Hard–-Weinberg
equilibrium P-values 410# 4 in controls and 410# 5 in combined cases
and controls (to exclude most genotyping errors), applying these
procedures in a stepwise approach separately for each data set. For each
of the separately derived control genotyping sets (Supplementary Table
S1), SNPs were excluded if they failed the above criteria within the
individual control set or in combination with any of the other control
groups, or in the complete data set. The Hard–Weinberg criteria were
applied after exclusion of non-European individuals (see Ancestry). Finally,
SNPs were excluded if allele frequency differed by 410% between
different control subject groups.
Table 5. Cumulative effect of risk and protective classical HLA alleles
for PBC susceptibility
Categorya Controls
number
(%)b
Cases
number
(%)
OR P-valuec
RISK—
PROTECTIVEp# 2
177 (12.3) 34 (5.0) 0.38 5.87E-08
RISK—
PROTECTIVE p# 1
682 (48.1) 185 (27.4) 0.50 2.03E-12
RISK—
PROTECTIVE¼ 0
522 (36.3) 246 (36.4) 1.00 NS
RISK—
PROTECTIVEX1
226 (15.7) 245 (36.2) 3.05 6.94E-25
RISK—
PROTECTIVEX2
32 (2.2) 72 (10.7) 5.25 1.37E-15
Abbreviations: AA, amino acid; HLA, human leukocyte antigen; OR, odds
ratio; PBC, primary biliary cirrhosis. aThis table shows the results of
categorizing each participant based on the sum of the each risk allele
(positive number) and each protective allele (negative number). The risk
alleles are DRB1*08, DRB1*14 and DPB1*03:01. The protective alleles are
DRB1*11 and DRB1*13. The alleles were determined from the most
probable allele after imputation and haplotype analyses (see Materials
and methods). bThe number of subjects that are in each category are
shown together with the % of total controls (1440) or percent of cases
(676). cThe two tailed Fisher exact P-value from contingency table analyses
comparing cases and controls in each category.
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Ancestry
European ancestry was determined using 883 genome-wide SNPs with
minimal or no LD (r2o0.1). SNPs analyzed using the STRUCTURE v2.1
program25 and subjects of known European, Amerindian, East Asian and
West African origin as previously described.26 We used STRUCTURE to
exclude non-European and admixed study participants, as this method
allows exclusion/inclusion criteria to be set using reference populations.
Subjects with 415% non-European ancestry were excluded from further
analysis.
Italian ancestry was defined using principal components (PCs) analyses.
For subjects with GWAS data, we used the same methods and criteria
applied in a previous study with largely the same data set. Briefly, PCs
analyses was performed using the EIGENSOFT statistical package,27
utilizing 34 000 SNPs distributed throughout the genome (r2o0.1) that
we have previously used to define population genetic substructure.2 These
analyses used an independent set of Italian subjects for establishing
membership (±2 s.d.) in first four PCs). In the current study, a substantial
portion of the samples did not have GWAS data (Supplementary Table S1).
For these samples, we used a set of 12 579 SNPs from the Immunochip for
which our empiric analyses demonstrated the ability of this set to discern
Italian ancestry and exclude both the other European ethnicities, including
Sardinian Italians (Supplementary Figure S1). Using the GWAS-defined
individuals, the Immunochip only genotyped samples were included using
2 s.d. in the first four PCs. In addition to the subject selection, we used the
eigenvalues from the first four PCs (only the first four PCs were significant
based on Tracy–Widom statistics) as covariates in our association analyses.
Imputation
We imputed SNPs, HLA classical alleles and HLA gene AAs using phased
reference genotypes from both the 1000 genome-sequencing project
(interim release June 2011) (http://www.1000genomes.org/) and an HLA-
defined reference set.8 For the 1000 genome imputation, we used IMPUTE
version 228 under default parameters. The reference haplotypes for this
imputation were from 1094 subjects, including 381 European subjects and
98 Tuscan Italians. The number of genotyped (inference) SNPs that
overlapped with the 1000 genome reference set ranged from 1435 SNPs
(samples typed by GWAS), 4386 (samples typed by Immunochip) to 4981
SNPs (samples typed by GWAS plus Immunochip) (Supplementary Table
S1). For subsequent data analyses, we utilized only imputed genotypes
with maximum posterior probability scores of40.90. Using this parameter,
our empiric testing (leave one-out analyses) indicated that the maximum
error rate for genotype assignment was o0.05, and the mean error rate
was o0.01. To impute classical HLA alleles and corresponding AAs
determinants, we utilized a reference separate data set of collected by the
Type 1 Diabetes Genetics Consortium. This reference data contains
genotype data for 2537 SNPs, selected to tag the entire major
histocompatibility complex, and classical types for HLA-A, B, C, DRB1,
DQA1, DQB1, DPA1 and DPB1 at 4-digit resolution in 2767 unrelated
individuals of European descent.29 The Beagle software package30 was
used for this imputation under default parameters. The number of
inference SNPs that overlapped with this reference data set ranged from
648 (samples typed by GWAS), 1444 SNPs (samples typed by Immunochip)
to 1610 SNPs (GWAS plus Immunochip) (Supplementary Table S1). Similar
to the imputation using 1000 Genome data, only SNPs with posterior
probabilities of 40.90 were included in our final analyses. For imputed
SNPs that overlapped between the two imputation sets and algorithms
used (Impute V2.0 and Beagle), there was a nearly complete concordance
of the association-testing results, indicating similar performance of these
algorithms for this data set. After imputation and selecting only those
markers meeting posterior probability criterion, this region contained a
total of 49 885 markers including the genotyped SNPs that were included
in association test analyses.
Association and conditional association tests of imputed SNPs and
HLA determinants
SNPTEST V2.028 (web) was used for the primary association analyses for the
imputed genotypes. This software uses the genotype probabilities for
the imputed SNPs or determinants and accounts for genotype uncertainty.
The first four PC eigenvalue scores were used as continuous variables in
the association test together with the gender covariate. Analyses were
performed using the SNPTEST v2 Score test algorithm that enabled both
the inclusion of the covariates and conditioning tests, and all of our
reported results used an additive model. To minimize potential spurious
results, we limited our main and conditioning analyses to markers with
information scores (Inf)40.85. This parameter is a measure of the observed
statistical information for the estimate of SNP allele frequency (for
additional information see https://mathgen.stats.ox.ac.uk/genetics_software/
snptest/snptest.v2.pdf).
Conditioning on multiple markers either separately or together was
performed using an additive model. For the HLA region, over 150
conditional analyses were performed using the SNPs and HLA determi-
nants, including all HLA determinants with P-values o10# 6.
Nominal P-values after correction for covariates and conditioning are
provided throughout the manuscript. The P-values o10# 6 would remain
significant after conservative (Bonferroni) correction for the number of
markers (o50 000) tested after imputation.
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